In 2013, approximately 84% of households in the United States reported detectable levels of dust mite allergens.
The Food and Drug Administration (FDA) has approved Dupixent (dupilumab; Sanofi and Regeneron) as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). The approval was based on data from two phase 3 randomized, double blind, placebo controlled trials (SINUS-24 and SINUS-52) that evaluated the safety and efficacy…
The clinician workgroup achieved a consensus and report a 3-step iterative management algorithm for MS relapses.
Age- and sex-stratified comorbidity and concomitant medication use has been found among individuals with MS who have newly initiated disease-modifying drugs.
Benralizumab has been found to be associated with a reduction in oral corticosteroid (OCS) use while maintaining asthma control for patients with OCS-dependent severe asthma.
List of therapeutic drug classes that are associated with significant weight gain and changes in fat distribution (lipodystrophy) and metabolism.
News, Safety Alerts and Recalls
Par is recalling 1 lot of Mycophenolate Mofetil for Injection (lot# AD812; expiration date: 9/2020) following the discovery of a glass fragment within a reconstituted vial.
The FDA has approved the use of Dupixent (dupilumab; Sanofi and Regeneron) to treat moderate-to-severe atopic dermatitis in adolescent patients 12–17 years old.
Treating osteoarthritis in older patients with tramadol vs nonsteroidal anti-inflammatory drugs may be associated with an increased mortality rate during the year following treatment initiation.
Regeneron and Sanofi announced that the Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP). The sBLA included data from two phase 3 randomized, double-blind, placebo-controlled trials (SINUS-24…